We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Scientists from Isis Pharmaceuticals have reported in Nature Medicine that the
STAT-3 gene is required for the generation of B-lymphomas in mice carrying a
mutation implicated in some human lymphomas and that reducing the expression
of STAT-3 with a second-generation antisense drug targeted to STAT-3 resulted
in impaired growth of human and mouse lymphoid tumors in animals.
MedImmune has announced preliminary Phase I clinical trial results of siplizumab
indicating the antibody was safe and well-tolerated in patients with certain
T-cell lymphomas and leukemias.
ViroPharma has begun a Phase Ib proof-of-concept clinical study in hepatitis
C-positive patients with HCV-796, a novel antiviral compound that the company
is co-developing with Wyeth Pharmaceuticals, a division of Wyeth.
Discovery Laboratories has reported additional long-term clinical data from its two Surfaxin Phase III clinical trials to treat respiratory distress syndrome (RDS) in premature infants, SELECT and STAR.
The FDA has approved Centocor's Remicade (infliximab) as a treatment for active
psoriatic arthritis, the ninth indication the agency has granted for the drug.
Cell Genesys has received a special protocol assessment (SPA) from the FDA for
its second Phase III clinical trial of GVAX vaccine for prostate cancer.